Cea-Targeted Car-T
Bile Duct Cancer
Chongqing Precision Biotech Co., LtdCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
19 Active assets in the Bile Duct Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Eloxatin Lisata Therapeutics, Inc. | Phase 2 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II Lisata Therapeutics, Inc. | Phase 2 | BB |
Dfn-15 Seoul National University Hospital | Phase 4 | B |
Pembrolizumab Imugene Limited | Phase 2 | B |
FLUOROURACILUM Lisata Therapeutics, Inc. | Phase 2 | B |
View all 30 →
Same molecule, other indications
Cea-Targeted Car-T is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →